Search
Quxin Biotech Secures $85 Million in Oversubscribed Series B Funding Round
1 day ago /
Read about 0 minute
Author：小编
Quxin Biotech has triumphantly concluded an oversubscribed Series B funding round, amassing $85 million. This financing endeavor was jointly spearheaded by Lilly Asia Ventures and Sanofi Ventures, with additional contributions from Sequoia Capital China and other esteemed investors. The infusion of capital will be strategically allocated to support the clinical progression of oral small molecule inhibitors specifically targeting STAT6 and IL-17. This move is set to propel the research and development of oral medications within the realms of immunology and inflammation, marking a significant stride forward in the company's pursuit of innovative therapeutic solutions.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
